PCN42 A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)- A UK PERSPECTIVE
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)66578-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)66578-3/fulltext
Title :
PCN42 A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)- A UK PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66578-3&doi=10.1016/S1098-3015(10)66578-3
First page :
Section Title :
Open access? :
No
Section Order :
411